CCM
CRBU icon

Coldstream Capital Management’s Caribou Biosciences CRBU Stock Holding History

Coldstream Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-504
Closed -$461 – 1610
2025
Q1 		$461 Buy
+504
New +$655 ﹤0.01% 3377

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coldstream Capital Management's CRBU Position: Q2 2025 in Review

Coldstream Capital Management sold out of Caribou Biosciences (CRBU) in Q2 2025, closing a stake of 504 shares — an estimated $461 sold.

Coldstream Capital Management first reported a position in CRBU in Q1 2025 and held it in 1 quarter. The position peaked at $461 in Q1 2025. 129 funds tracked by Wall St. Rank hold CRBU as of Q2 2025.

  • Coldstream Capital Management reported no remaining Caribou Biosciences position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 504 Caribou Biosciences shares in Q2 2025, an estimated $461.
  • Coldstream Capital Management first reported a position in Caribou Biosciences in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Caribou Biosciences position peaked at $461 in Q1 2025.
  • 129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.